Patient Safety–A Sustained Focus from Scientific Ideas to Innovative Medicines–will be the main theme for discussion when pharmaceutical and health care professionals from around the world meet for the 5th DIA China Annual Meeting.
The 5th DIA China Annual Meeting, co-sponsored by the China Center for Pharmaceutical International Exchange (CCPIE) of the State Food and Drug Administration (SFDA), will be held at the Beijing International Convention Center from May 12 to 15.
The meeting, featuring more than 40 sessions and 60 exhibitors, will bring together professionals from the pharmaceutical and biopharmaceutical industries, contract research and service organizations, regulatory agencies and academic institutes on a neutral global platform. Attendees will share knowledge and experience focusing on better public health protection, patient benefits, best practices and compliance in alignment with science and regulations.
Program Co-chair Dr Lingshi TAN, Vice President, Pfizer Worldwide Development Operations, said: “The China Annual Meeting helps to enhance communication and collaboration between China and the world. This year’s sessions will highlight the latest developments within the pharmaceutical industry in China, explore ideas that will impact global health, and feature open debates among senior professionals, top academics, and high-level officials from various fields in medicine development. Patient safety will be reinforced as a core element of therapeutic innovation and a key philosophy throughout the life cycle of pharmaceutical and biopharmaceutical management.”
Program Co-chair Yajun ZHAO, Director-General, China Center for Pharmaceutical International Exchange, SFDA, said: “Drug safety is the pivotal mission of China’s drug regulatory agencies and will be the main theme of the DIA China Annual Meeting, alongside patient care. The China Annual Meeting will be an extraordinary platform for exchange between drug regulatory agencies, industry, and academic institutes exploring ideas to ensure drug safety and protect people’s health.”
The key themes include:
- Chemistry, Manufacturing and Controls (CMC)
- Clinical Research and Operations
- Data Management
- Drug Safety and Pharmacovigiliance
- Regulatory Science
- The Pathway to Success for CROs and SMOs in China
- Vaccine and Biologics
NNew themes and topics include:
- SFDA Townhall Meeting
- Regulatory and Drug Safety Joint Program: Balancing Risk and Benefit during NDA and Post-Marketing Periods
- Botanical Drug Products in China and the United States
- Future Oncology Drug Development: Opportunities and Challenges
- Pharmacoepidemiology – Best Practices and Drug Safety
- Post-approval Studies
- Development of Novel Traditional Chinese Medicines (TCM) for China and Global Markets
For more information about the China Annual Meeting or to register, visit www.diachina.org.
Companies interested in exhibition, hosting opportunities, and advertisements at the 5th China Annual Meeting email firstname.lastname@example.org
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA. USA, with offices in Washington DC, USA, Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China.
Contact: Laura Hollis